Zydus receives final approval from USFDA for Telmisartan, Hydrochlorothiazide Tablets

17 Aug 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Telmisartan and Hydrochlorothiazide Tablets USP, in the strengths of 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg. Telmisartan and Hydrochlorothiazide Tablets are used to treat hypertension (high blood pressure). The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The sales of Telmisartan and Hydrochlorothiazide Tablets is estimated at $66.5 million, as per IMS Health MAT June 2017. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.



Zydus Lifesciences Share Price

918.35 4.45 (0.49%)
17-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.10
Dr. Reddys Lab 1272.00
Cipla 1496.95
Zydus Lifesciences 918.35
Lupin 2113.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×